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SUMMARY
Background
Infliximab and adalimumab have established roles in inflammatory bowel dis-
ease (IBD) therapy. UK regulators mandate reassessment after 12 months’ anti-
TNF therapy for IBD, with consideration of treatment withdrawal. There is a
need for more data to establish the relapse rates following treatment cessation.
Aim
To establish outcomes following anti-TNF withdrawal for sustained remis-
sion using new data from a large UK cohort, and assimilation of all avail-
able literature for systematic review and meta-analysis.
Methods
A retrospective observational study was performed on 166 patients with
IBD (146 with Crohn’s disease (CD) and 20 with ulcerative colitis [UC)
and IBD unclassified (IBDU)] withdrawn from anti-TNF for sustained
remission. Meta-analysis was undertaken of all published studies incorpo-
rating 11 further cohorts totalling 746 patients (624 CD, 122 UC).
Results
Relapse rates in the UK cohort were 36% by 1 year and 56% by 2 years for CD,
and 42% by 1 year and 47% by 2 years for UC/IBDU. Increased relapse risk in
CD was associated with age at diagnosis [hazard ratio (HR) 2.78 for age
<22 years], white cell count (HR 3.22 for >5.25 9 109/L) and faecal calprotectin
(HR 2.95 for >50 lg/g) at drug withdrawal. Neither continued immunomodula-
tors nor endoscopic remission were predictors. In the meta-analysis, estimated
1-year relapse rates were 39% and 35% for CD and UC/IBDU respectively.
Retreatment with anti-TNF was successful in 88% for CD and 76% UC/IBDU.
Conclusions
Assimilation of all available data reveals remarkable homogeneity. Approxi-
mately one-third of patients with IBD flare within 12 months of withdrawal
of anti-TNF therapy for sustained remission.
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INTRODUCTION
Tumour necrosis factor (TNF) antagonists, notably inflix-
imab (IFX) and adalimumab (ADA) are firmly established
induction and maintenance agents in Crohn’s disease
(CD) and ulcerative colitis (UC).1–4 The European
Crohn’s and Colitis Organisation (ECCO) recommend
their use for CD that is refractory to steroids or relapses
after initial therapy, as second-line therapy in patients
with acute severe UC and in patients with immunomodu-
lator-refractory UC.5, 6 However, despite the advent of
biosimilar infliximab, the drugs are expensive (approxi-
mately £6–10 000 per annum)7 and there remain some
concerns over long-term safety. Serious potential adverse
effects include immunogenicity, opportunistic infections,
melanoma.8, 9 Once sustained deep remission has been
achieved on maintenance anti-TNF therapy clinicians,
patients and payers may all have different motivations for
a trial of drug withdrawal. Indeed in the UK, the National
Institute for Clinical Excellence (NICE) and the Scottish
Medicines Consortium (SMC) mandate reassessment at
12 monthly intervals with a consideration of drug cessa-
tion where patients are in stable remission. However,
there is presently insufficient data on relapse and recap-
ture rates to inform such decision making.9–12 We there-
fore aimed to examine the rate of disease relapse in IBD
patients utilising all available data. We recruited a large
retrospective uncontrolled cohort of patients from the
UK, all withdrawn from anti-TNF therapy for sustained
clinical remission, and assessed possible predictive factors
for relapse and the success of drug reintroduction. We
then performed a systematic review of the published liter-
ature and conference abstracts with a meta-analysis of all
relevant data.
SUBJECTS AND METHODS
Study design
A multi-centre retrospective clinical audit was conducted
using patients identified from 21 IBD centres across the
UK. A detailed review of case notes was performed using
a standardised proforma and study guide, accessible
through the www.ibdscotland.org website. Data were
extracted detailing patient demographics including: sex,
diagnosis (CD/UC/IBDU), date of and age at diagnosis,
weight (at withdrawal) and smoking status. Drug therapy
details gathered include: anti-TNF used, start date, age
when started, original approach of therapy, initial and
maintenance dosages, stop date, age at withdrawal, taper-
ing at withdrawal and concomitant medication. Parame-
ters at withdrawal included: reason for withdrawal, date
of last symptomatic flare and course of systemic corticos-
teroids prior to withdrawal, Montreal classification and
behaviour, laboratory markers [faecal calprotectin, C-
reactive protein (CRP), haemoglobin, platelets, erythro-
cyte sedimentation rate (ESR), white cell count (WCC),
albumin], endoscopic findings and abdominal imaging.
Endoscopic findings were given as free text by the indi-
vidual sites and coded centrally by a single researcher as
quiescent mild, moderate or severe. Formal assessment
of the endoscopic appearances using a validated score
was not deemed feasible. Relapse was also recorded, not-
ing the severity, anti-TNF reintroduction and need for
additional treatment. Eligible patients were identified for
the study by searching IBD databases and out-patient
clinic lists at the participating centres.
Patients with IBDU and UC were analysed as a single
group since numbers of each individually were small.
Study criteria
Inclusion criteria were: confirmed diagnosis of IBD, at
least 12 months of continuous anti-TNF therapy, with-
drawal for sustained clinical remission and corticos-
teroid-free remission for at least 6 months at time of
withdrawal. Patients meeting inclusion criteria were iden-
tified at each study site, and their suitability for inclusion
was checked centrally based on the reported reasons for
drug withdrawal and timing of last symptomatic flare,
drug withdrawal and follow-up. Each study site was asked
to identify patients by screening all of their patients trea-
ted at any time with anti-TNF in order to reduce bias.
Disease relapse was classified as either moderate or
severe. Moderate relapse was defined by the requirement
of oral steroids, immunomodulators or recommencement
of anti-TNF therapy. Hospital admission, IV steroids
and resectional surgery defined severe relapse.
The pre-specified primary end-point was a moderate–
severe relapse at 12 months while secondary end-point
was moderate–severe relapse at 24 months.
Statistical analysis
Data were collected by each site in a Microsoft Excel
spreadsheet (Microsoft Corp, Redmond, WA, USA) and
submitted to the lead site. Anonymised data were then
collated in a single master spreadsheet. Each entry was
rechecked to make sure they met the inclusion criteria.
Data were analysed using R 3.1.3 (R Foundation for Sta-
tistical Computing, Vienna, Austria). Survival analysis
including Cox proportional hazards and Kaplan–Meier
analysis were done using the survival package.13, 14 The
overall moderate-to-severe relapse rates were estimated
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using the Kaplan–Meier method. These were divided
into moderate and severe relapse based on the propor-
tions of relapses of each category by that time point.
For Cox proportional hazards analysis, continuous
variables were analysed using untransformed values for
those with approximately normal distributions, and log-
transformed values for those with approximately log-nor-
mal distributions (CRP and faecal calprotectin). For uni-
variable analysis of variables with missing data, only
individuals with known data were included. Colono-
scopies were categorised as quiescent, mild and moderate
inflammation, and for statistical analysis were split into
no inflammation vs. a mild or greater degree of inflam-
mation. Blood tests were only analysed for those patients
without an additional reason for anti-TNF withdrawal
which might have influenced the results. Continuous
variables that were significant on univariable analysis
were also analysed as a categorical variable using a
threshold derived that gave the highest sum of sensitivity
and specificity for predicting relapse at 12 months. Mul-
tivariable analysis was performed on variables with
P < 0.1 on univariable analysis and with at least 100
individuals with data. After creating an initial model,
backwards step-wise regression was performed using the
Akaike An Information Criterion (AIC) to select which
variables to keep. A second model was created which
also included faecal calprotectin, since it was one of the
most significant and clinically relevant markers; this
could only include the subset of patients with faecal cal-
protectin results.
Systematic review
Criteria for including studies. Types of studies: Retro-
spective or prospective uncontrolled or controlled studies.
Types of participants: Patients with IBD withdrawn
from anti-TNF therapy after a period of sustained clini-
cal remission (at least 6 months).
Types of interventions: Withdrawal of anti-TNF therapy.
Types of outcome measures: Proportion of patients
experiencing clinical relapse by 1 year following treat-
ment withdrawal.
Exclusion criteria: Studies without an estimate of 1-year
relapse; studies where the outcome measure was endo-
scopic recurrence rather than clinical relapse; studies
where anti-TNF was being used as post-operative pre-
vention of recurrence.
Search methods for identification of studies. Computer-
assisted searches of PubMed and EMBASE were carried
out covering the years 1950–2015 (PubMed) and 1980–
2015 (EMBASE). PubMed search terms used were:
Search (anti-TNFa OR antiTNF OR antiTNFa OR “anti-
tumour necrosis” OR “anti-tumor necrosis” OR inflix-
imab OR adalimumab OR anti-TNF OR golimumab OR
certolizumab) AND (withdrawal OR discontinuation OR
cessation OR stopping OR de-escalation) AND (inflam-
matory bowel disease OR IBD OR Crohn’s OR colitis
OR Crohn). EMBASE was searched using the same strat-
egy, but combining three searches together with the
AND operator. No limits were imposed on either type of
search, and searches were last updated on 6 March 2015.
Where available, EMBASE search results were assigned
PubMed IDs using the PubMed batch citation tool. The
results of all searches were then merged with those from
PubMed and duplicates removed by matching PubMed
IDs and manual matching of titles/journals. Where an
identical abstract had been presented at two or more
conferences, these were also regarded as duplicates.
EMBASE includes conferences from 2009 onwards.
Data collection and analysis: All titles identified by the
above searches were reviewed. Abstracts and full texts of
relevant papers that related to withdrawal of anti-TNF in
IBD were reviewed to identify independent data sets that
met the inclusion criteria. Data were extracted and
stored in an Excel spreadsheet by a single researcher
(NAK). Studies were assessed as to whether they were
prospective or retrospective, controlled or uncontrolled.
Data extracted included an estimate of the 12-month
relapse rate (controlling for loss-to-follow-up where rele-
vant) and variables predictive of relapse.
Meta-analysis
Meta-analysis was performed using the metafor package
in R 3.2.2.15 Proportions were used as the measure of
effect size and a random effects model to estimate the
average proportion. Weighting was done with the inverse
variance method. Proportion data were transformed using
the arcsine square root transformation and reverse trans-
formed for display. 0.5 was added to each count where
there was a zero (e.g. in the situation of 100% success with
retreatment). Heterogeneity was estimated using the
restricted maximum-likelihood estimator. An I2 of less
than 40% was regarded as likely to be unimportant.16 A P
value for heterogeneity was also calculated using
Cochran’s Q method.17 Publication bias was assessed
using a funnel plot. The primary analysis was performed
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using studies that included patients with at least
12 months’ therapy. A further analysis was performed
also including studies with a shorter minimum time on
anti-TNF, though still only examining studies where
patients were withdrawn from maintenance therapy.
RESULTS
Retrospective UK cohort
Out of the 21 centres across the UK, 166 patients, 146
with CD and 20 with UC/IBDU, were eligible for inclu-
sion (Table 1). A further 19 patients were submitted but
excluded from analysis, most commonly for less than
12 months’ therapy or missing data. The number of
screened patients was not available across most sites, but
for Edinburgh 380 patients were screened to identify 10
that met the inclusion criteria with the majority of the
remainder either continuing with anti-TNF (n = 147) or
having been withdrawn for reasons other than sustained
remission (n = 155).
One hundred and seventeen (80%) CD patients and 19
(95%) UC/IBDU patients were on infliximab prior to
withdrawal; the remainder were on adalimumab. The
median time taken for introducing anti-TNF therapy post-
Table 1 | Demographics of patients in the UK retrospective study
Crohn’s disease (n = 146) Ulcerative colitis/IBDU (n = 20)
Anti-TNF used
Infliximab 117 (80%) 19 (95%)
Adalimumab 29 (20%) 1 (5%)
Sex
Female 83 (57%) 8 (40%)
Age at anti-TNF withdrawal/years 31 (24–42) 40 (29–46)
Reason for starting anti-TNF
Failure of immunomodulators 117/139 (84%) 14/18 (78%)
Early combination therapy 7/139 (5%) 0
Early monotherapy 3/139 (2%) 0
Hospitalisation for acute severe disease 5/139 (4%) 4/18 (22%)
Other 7/139 (5%) 0
Time on anti-TNF/months 29 (18–45) 21 (14–33)
Follow-up time since withdrawal/months 24 (15–38) 23 (15–35)
Year stopped anti-TNF 2012 (2010–2012) 2012 (2011–2013)
Smoking at withdrawal
Current 14/129 (11%) 1/17 (6%)
Ex 18/129 (14%) 3/17(18%)
Never 97/129 (75%) 13/17 (76%)
Montreal location
L1  L4 18/142 (13%)
L2  L4 38/142 (27%)
L3  L4 81/142 (57%)
L4 5/142 (4%)
Montreal behaviour
B1 98/142 (69%)
B2 21/142 (15%)
B3 23/142 (16%)
Montreal extent
E2 9/19 (47%)
E3 10/19 (53%)
Previous surgical resection for IBD 35/125 (28%) 0/17 (0%)
Therapy at withdrawal
Azathioprine 66/146 (45%) 12/20 (60%)
Mercaptopurine 9/145 (6%) 1/20 (5%)
Methotrexate 20/145 (14%) 2/20 (10%)
Mesalazine 17/146 (12%) 7/20 (35%)
Any of the above 107/145 (73%) 16/20 (80%)
Numbers shown are medians and interquartile ranges or numbers and percentages as appropriate. Percentages have been calcu-
lated after exclusion of missing data within each category.
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diagnosis was 63 months for CD [interquartile range
(IQR) 30–122] and 22 months for UC/IBDU (IQR 10–
70). Median therapy duration prior to withdrawal was
29 months (IQR 18–45) for CD and 21 months for UC/
IBDU (IQR 14–33). Median follow-up was 24 months
(IQR 15–38) for CD and 23 months (IQR 15–35) for UC/
IBDU. Investigations at withdrawal are shown in Table 2.
The majority of patients in both disease groups (80%
CD, 78% UC/IBDU) commenced anti-TNF following
failure of immunomodulators. Among the CD cohort,
69% had inflammatory (Montreal B1) disease, with the
remainder split between stricturing (B2) and penetrating
(B3). While all patients had to be in clinical remission
for 6 months at the point of treatment withdrawal, there
was an additional factor that influenced the decision for
withdrawal in 21 (14%) CD patients and 1 (5%) UC/
IBDU patient, including planned pregnancy or mild drug
intolerance (Table S1).
Relapse rate and predictive factors
By time of last follow-up, 75/146 (51%) CD patients and
9/20 (45%) UC/IBDU patients had experienced relapse
(Figure 1). By 12 months, the estimated moderate-to-
severe relapse rate was 36% in CD [95% confidence
interval (CI) 29–44] and 42% in UC/IBDU (95% CI 15–
60) at 12 months. By 24 months, the estimated relapse
rates had increased to 56% in CD (95% CI 46–64) and
47.1% in UC/IBDU (95% CI 19–65). There was no sig-
nificant difference in relapse rates between CD and UC/
IBDU (P = 0.95).
Predictive factors assessed for relapse are shown in
Table 3. Relapse in CD was associated with younger age at
diagnosis (P = 0.007), white cell count at time of anti-
TNF withdrawal (P = 0.013), isolated L4 disease
(P = 0.005), absence of perianal disease (P = 0.045), Mon-
treal behaviour B2 (P = 0.024) and log (faecal calpro-
tectin) (P = 0.041). Stratifying patients into groups based
on faecal calprotectin with a cut-off of 50 lg/g showed
clear separation of the survival curves, with P = 0.006
(Figure 2). On multivariable analysis of variables with uni-
variable P < 0.1 and n > 100 (Table 3b), age at diagnosis
(P = 0.002) and white cell count >5.25 9 109 (P = 0.022)
remained significant. This analysis included the 128
patients with data for all included variables faecal calpro-
tectin >50 lg/g was also significant when included in a
multivariable model (P = 0.016), though this reduced the
number of assessable patients to 42. A score comprised of
white cell count, age at diagnosis and faecal calprotectin
using the thresholds described above showed significant
separation of survival curves (P < 0.001, Figure 3).
There were no associations with any predictive factors
for UC/IBDU.
Consequences of relapse and re-treatment
Among the 48 CD patients who relapsed in the first
12 months, 22 (46%) required systemic corticosteroid
therapy, 7 (15%) required hospital admission and 1 (2%)
underwent surgery. Among UC/IBDU patients relapsing
in the first 12 months, four (50%) required systemic cor-
ticosteroids and 1 (12%) underwent colectomy.
Reintroduction of anti-TNF therapy
Anti-TNF therapy was reintroduced in 56/75 (75%) CD
patients and 3/9 (33%) UC/IBDU patients with relapse.
Table 2 | Investigations at withdrawal of anti-TNF in the UK retrospective study
Crohn’s disease Ulcerative colitis/IBDU
n Median (IQR) or n (%) n Median (IQR) or n (%)
Haemoglobin (g/L) 133 137 (128–146) 20 132 (126–142)
White cell count (109/L) 133 6.2 (5.0–7.4) 20 6.6 (5.4–8.0)
Platelet count (109/L) 133 256 (213–299) 20 260 (216–351)
Albumin (g/L) 128 44 (40–46) 19 39 (37–44)
CRP (mg/L) 129 2.5 (1.5–3.0) 18 2.2 (1.5–4.5)
Faecal calprotectin (lg/g) 46 46 (20–91) 3 <20 (<20–334)
Colonoscopy
Quiescent 84 74 (88%) 16 12 (75%)
Mild 9 (11%) 2 (12%)
Moderate 1 (1%) 2 (12%)
For all blood tests, patients were only included in this analysis if they had no additional reasons for anti-TNF withdrawal (n = 138
for Crohn’s disease and 20 for ulcerative colitis/IBDU). No full blood count was performed at withdrawal on five CD patients
(three of whom were children). Colonoscopy was performed on 84 of the Crohn’s disease patients and 16 of the ulcerative col-
its/IBDU patients.
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The same anti-TNF was reintroduced in 47/56 (84%) CD
patients and 3/3 (100%) UC/IBDU patients, with the
remainder switching from infliximab to adalimumab.
Reintroduction was deemed successful in 52/56 (93%)
with CD and 2/3 (67%) with UC/IBDU. However, in 21 of
these 52 CD patients (40%) systemic steroids were also
required, and in 2/52 (4%) resectional surgery was needed.
None of the three UC/IBDU patients in whom anti-TNF
was introduced required surgery, though the unsuccessful
UC/IBDU patient required systemic steroids.
Systematic review
Initial searches and review of bibliographies identified
2629 papers after removal of duplicates (Figure 4). Six-
teen studies were deemed eligible for inclusion in the
meta-analysis in addition to the present study. Overall,
12 studies covered CD only, 1 UC only and 4 both dis-
eases (Table S2, excluded studies in Table S3). All of the
included studies were uncontrolled observational studies,
with a mixture of prospective and retrospective
approaches. Twelve studies met the inclusion criteria for
the primary meta-analysis (at least 12 months’ anti-TNF
therapy prior to withdrawal).
Meta-analysis
In the primary meta-analyses, 624 CD patients from 10
studies and 122 UC/IBDU patients from 4 studies were
included. The estimated average 12-month relapse rate
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Figure 1 | Survival analysis of relapse following withdrawal of anti-TNF for sustained remission of Crohn’s disease (a)
and ulcerative colitis/IBD unclassified (b) in the UK retrospective study.
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Table 3 | Predictive factors for relapse after withdrawal from anti-TNF in Crohn’s disease using Cox proportional
hazards model in the UK retrospective study. (a) univariable analysis; (b) multivariable analysis
(a)
n HR (95% CI) P
Sex
Male 146 1.22 (0.77–1.93) 0.389
Smoking at withdrawal
Never 129 Reference
Current 1.29 (0.65–2.56) 0.459
Ex 0.72 (0.32–1.59) 0.416
Age at diagnosis (years) 144 0.97 (0.94–0.99) 0.007
Age at diagnosis < 22 years 144 2.71 (1.66–4.43) <0.0001
Age when starting anti-TNF (years) 145 0.98 (0.96–1.00) 0.046
Additional reason for anti-TNF withdrawal 146 0.66 (0.32–1.38) 0.270
Tapered at withdrawal 145 1.02 (0.37–2.79) 0.975
Montreal location
L1 142 Reference
L2 1.82 (0.72–4.58) 0.203
L3 2.05 (0.87–4.84) 0.100
L4 5.43 (1.65–17.93) 0.005
Montreal behaviour
B1 142 Reference
B2 1.93 (1.09–3.40) 0.024
B3 0.52 (0.24–1.09) 0.084
Perianal disease 142 0.54 (0.30–0.99) 0.045
Immunomodulator at withdrawal 146 0.68 (0.43–1.08) 0.101
Immunomodulator or 5ASA at withdrawal 146 0.77 (0.47–1.28) 0.316
Previous surgical resection 125 1.44 (0.86–2.39) 0.163
Haemoglobin (g/L) 133 1.01 (0.99–1.04) 0.147
White cell count (109/L) 133 1.16 (1.03–1.30) 0.013
White cell count >5.25 9 109/L 133 2.54 (1.39–4.66) 0.003
Platelet count (109/L) 133 1.00 (1.00–1.01) 0.326
CRP [log10 (mg/L)] 129 0.83 (0.44–1.55) 0.557
Albumin (g/L) 128 1.00 (0.94–1.05) 0.891
Faecal calprotectin >50 lg/g 46 3.32 (1.42–7.79) 0.006
Faecal calprotectin [log10 (lg/g)] 46 1.82 (1.03–2.82) 0.041
Inflammation at colonoscopy 84 0.93 (0.39–2.20) 0.863
(b)
Model without calprotectin
(n = 128) Model with calprotectin (n = 42)
HR (95% CI) P HR (95% CI) P
Age at diagnosis <22 years 2.29 (1.35–3.88) 0.002 2.78 (1.11–7.00) 0.03
Montreal behaviour
B1 Reference
B2 1.60 (0.88–2.90) 0.200
B3 0.51 (0.24–1.09) 0.089
White cell count >5.25 9 109/L 2.06 (1.11–3.80) 0.022 3.22 (0.95–10.93) 0.06
Faecal calprotectin >50 lg/g 2.95 (1.22–7.12) 0.02
HR, hazard ratio; CI, confidence interval.
P values less than 0.05 are highlighted in bold. For continuous variables, hazard ratios shown are for each unit increase for age,
haemoglobin, white cell count, platelet count and albumin. For CRP and calprotectin which have a log-normal distribution, hazard
ratios shown are for each 10-fold increase.
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was 39% for CD (95% CI 35–44) and 35% for UC/IBDU
(95% CI 26–43) (Figure 5). Both data sets had low
heterogeneity, with I2 = 12% for CD and 0% for UC/
IBDU. Expanding the inclusion criteria to include
patients with shorter periods on anti-TNF prior to drug
withdrawal increased the heterogeneity to I2 = 40% for
CD and 56% for UC (Figure S1).
For CD, the estimated average 24-month relapse rate
was 54% (95% CI 49–59) when using the four studies
with relevant data that met the primary inclusion criteria
(Figure S2A). Extending this to all eight studies with
available data gave a similar estimated average relapse
rate of 53% (95% CI 49–57) (Figure S3). For UC, there
were only two studies with 24-month relapse date. The
estimated average relapse rate was 42% (95% CI 27–58)
(Figure S2B).
The estimated average rate of success of retreatment
was 88% for CD (95% CI 78–95) and 76% for UC/IBDU
(95% CI 56–92) (Figure S4). For CD, there was signifi-
cant heterogeneity of retreatment success (I2 = 73%,
P < 0.01), though this disappeared when the Monterub-
bianesi18 study was removed (I2 without Monterub-
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bianesi study 38%, P = 0.21). For UC, the total numbers
were low (28 individuals across three studies) and so the
confidence intervals were wide.
A funnel plot to assess for publication bias was sym-
metric for CD (Figure S5), though there was a single
outlier (the paediatric Wynands et al. study19). There
were too few points to make a meaningful assessment of
publication bias for UC/IBDU.
DISCUSSION
In patients with IBD withdrawn from anti-TNF therapy
while in sustained remission, our meta-analysis has
shown a clinical relapse rate by 12 months of 39% for
CD and 37% for UC/IBDU. For CD, the 24-month
relapse rate was 54%. These estimates are based on our
large UK retrospective uncontrolled cohort and assimila-
tion of all presently available and relevant data from the
literature. The meta-analysis reported herein is remark-
able for the lack of heterogeneity among the individual
data sets. With the important caveat that relatively fewer
UC patients were available for analysis, the relapse rates
are broadly similar to those observed in CD.
These data will give confidence to clinicians when dis-
cussing with patients established on anti-TNF therapy
the chances of disease flare if the drugs are withdrawn.
Approximately one in three patients with any form of
inflammatory bowel disease are likely to experience a
moderate-to-severe flare within 12 months of drug with-
drawal, and one in two by 24 months. These odds are
likely to seem unfavourable to many clinicians and
patients but should prove useful when set alongside
other key factors. These might include how the timing of
drug withdrawal fits in with a patient’s life (e.g. impor-
tant education, work, or family events). In some coun-
tries, such as parts of the UK, drug withdrawal will be
recommended by regulatory authorities.
Two other key pieces of information are likely to be
useful to fully inform clinical teams about making key
alterations in drug therapy. Firstly, if a patient does
experience a disease flare following drug withdrawal,
what are the consequences of this and how successful is
reintroduction of drug therapy? Our large UK cohort
offers some useful guidance on this. While just under
one half of all patients who relapsed required systemic
corticosteroids, hospitalisation rates were relatively low
(17% in CD, zero in UC) and surgical rescue was a rare
event (only two patients). When anti-TNF therapy was
restarted it was deemed to be successful in over 90% of
patients with CD. These results were confirmed in the
meta-analysis, with an estimated retreatment success rate
of 88% (95% CI 78–95). There was a single outlying
study (Monterubbianesi18); the reasons for this are
unclear, particularly since this study has only been pub-
lished as a conference abstract, but may reflect different
criteria for retreatment success. We have insufficient data
to draw any meaningful conclusions in UC.
Secondly, what are the predictive factors of relapse at
the time of drug withdrawal? Arguably this is the most
PubMed search
421 results
Dupicates removed
2629 titles reviewed
341 abstracts reviewed
108 full texts reviewed
10 selected for
primary meta-
analysis
6 additional
papers selected
for secondary
meta-analysis
23 additional
papers selected
for inclusion in
paper but not
meta-analysis
Other full texts excluded
24 review, editorial or
               letter with no new data
13 data included
elsewhere
withdrawal
withdrawal
sustained remission
1   withdrawal not for
1   expert guideline
1   case report
full text
8   review, no data on
4   review, unable to access
2   no follow-up post-
Data from these 16 studies analysed
alongside that from the present UK
cohort
EMBASE search
2664 results
Additional papers from
review of literature
3 results
Figure 4 | Inclusion flowchart for systematic review/meta-analysis.
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important piece of information to enable rationale strati-
fication of patients at drug withdrawal. In our cohort on
multivariable analysis, younger age at diagnosis, white
cell count and faecal calprotectin were predictive of
relapse at 12 months in CD. In contrast, evidence of dis-
ease activity at colonoscopy was not predictive, though
only 12% of those colonoscoped had any evidence of dis-
ease activity. In fact, of the six factors identified in the
simplified model of the STORI study, only faecal calpro-
tectin and white cell count were significant in the present
study.20 L4 disease was also predictive, but the generalis-
ability of this finding is limited by the small numbers in
that disease group (five patients).
At a fundamental level we still cannot address the
question of whether evidence of active disease at drug
withdrawal predicts disease relapse. Central to this para-
dox is the question whether patients on anti-TNF ther-
apy with complete mucosal healing are in complete
remission because of their ongoing therapy or in spite of
it. One might expect those patients who exhibit ongoing
Study
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Figure 5 | Forest plot for relapse by 12 months after anti-TNF withdrawal for CD (a) and UC/IBDU (b).
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mucosal inflammation despite being in complete clinical
remission to be at much higher risk of disease relapse
following drug withdrawal. In our study, a faecal calpro-
tectin above 50 lg/g was predictive in the Crohn’s
cohort of relapse (HR 3.32, P = 0.006). faecal calpro-
tectin was also found to be predictive in the STORI
study,20 while Bortlik et al. found no association of fae-
cal calprotectin with relapse.21 Inconsistencies across the
literature in large part reflect that in most cohorts very
few patients had any objective evidence of mucosal
inflammation at drug withdrawal. The data from our
study are typical: 83% of patients had a normal CRP and
88% a calprotectin <250 lg/g with 60% having calpro-
tectin <50 lg/g. Although white cell count was an inde-
pendent predictive factor in this cohort, the optimum
threshold was well within the normal range at
5.25 9 109/L (and was not related to immunomodulator
use). In addition, full colonoscopic assessment, where it
was performed, was completely normal in 86/100. This
is despite clinical remission at the time of drug with-
drawal being the only major inclusion criterion in our
protocol. Clinicians are evidently continuing therapy in
patients where there is evidence of ongoing inflamma-
tion, often in spite of drug optimisation. For many, this
will reflect a lack of alternative therapeutic options.
However, there are likely to be a substantial number of
patients in whom anti-TNF therapy can be discontinued
in this scenario as it is having no discernible impact on
the disease course. This is highlighted by results from
the STORI trial where undetectable infliximab trough
levels were associated with a lower risk of subsequent
relapse on drug withdrawal.20 Further prospective clinical
trials are planned to address these key issues.
The limitations of our UK cohort are its retrospective
nature, and the missing data at the time of drug with-
drawal. CRP, calprotectin and colonoscopic assessment
were available in 93%, 30% and 60% of patients. The rel-
atively low number of abnormal colonoscopies may have
limited the power of the study for this predictive marker.
Details of small bowel imaging were only available in 30
patients, and the data were too heterogeneous (ultra-
sound, CT, MRI, barium studies) to allow meaningful
analysis. All sites were asked to be thorough in their
searches of anti-TNF-treated patients to reduce the risk
of selection bias, but this remains a potential concern. In
Edinburgh, where the lead authors are based, it should
be noted that even with comprehensive review of our
patient cohort, it was in practice very difficult to identify
patients who met our criteria. This suggests that despite
NICE guidance, relatively few patients with IBD have
their anti-TNF therapy stopped for sustained remission.
It is also of note that 75% of CD patients in the UK
cohort were never smokers, which is lower than reported
elsewhere.22–24 This may reflect clinician concerns about
relapse rates in smokers whose anti-TNF therapy is with-
drawn.
We have been thorough in our systematic review and
followed strict criteria and guidelines for the selection of
studies for the meta-analysis. However, all of the included
studies were uncontrolled and many were retrospective. It
is therefore not possible to draw conclusions about what
would have happened in the absence of drug withdrawal.
For the retrospective cohorts in particular, there is a risk
of recall bias, which could inflate or reduce estimates of
relapse rate in those cohorts; however, there was no signif-
icant difference in the 12-month relapse rate between
prospective and retrospective cohorts.
We are, however, able to draw several important con-
clusions based on a synthesis of all available data.
Approximately one-third of patients with CD or UC in
sustained clinical remission are likely to suffer a disease
relapse within 12 months of planned drug withdrawal.
We are presently unable to predict which patients are
most likely to flare in this situation. We can recapture
disease remission by restarting anti-TNF therapy in the
majority of patients, although nearly half may also
require a course of corticosteroids. Clinicians and
patients should weigh up the decisions about drug with-
drawal on an individual basis taking into account the
preceding disease course, and the appropriate time in a
patient’s life for such critical therapeutic changes.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Table S1. Detailed reasons for withdrawal from anti-
TNF.
Table S2. Characteristics of articles included in sys-
tematic review and meta-analysis of withdrawal of anti-
TNF for sustained clinical remission, sorted by year of
publication. (A) Studies with at least 1 year anti-TNF
prior to withdrawal. (B) Studies with maintenance ther-
apy but <1 year anti-TNF at withdrawal. C: Studies
included in secondary meta-analysis but excluded from
primary meta-analysis for other reasons.
Table S3. Studies excluded from meta-analysis.
Figure S1. Forest plot for relapse by 12 months after
anti-TNF withdrawal for CD (A) and UC/IBDU (B)
including all studies with patients treated with mainte-
nance anti-TNF.
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Figure S2. Forest plot for relapse by 24 months after
anti-TNF withdrawal for CD (A) and UC/IBDU (B)
including only studies with patients treated with mainte-
nance anti-TNF for at least 12 months.
Figure S3. Forest plot for relapse by 24 months after
anti-TNF withdrawal for CD including all studies of
patients treated with maintenance anti-TNF.
Figure S4. Forest plot for success rates of reintroduc-
tion of anti-TNF after withdrawal for CD (A) and UC/
IBDU (B) including all studies with patients treated with
maintenance anti-TNF.
Figure S5. Funnel plot for relapse by 12 months after
anti-TNF withdrawal including studies with patients
treated with maintenance anti-TNF for at least one year
prior to withdrawal.
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